期刊文献+

GP方案与NP方案治疗晚期非小细胞肺癌的Meta分析 被引量:7

Meta-analysis of GP and NP regimen in advanced non-small cell lung cancer
下载PDF
导出
摘要 目的比较临床治疗非小细胞肺癌最常用的一线化疗方案的临床选择对患者的获益性,系统评价GP(吉西他滨联合顺铂)方案与NP方案(长春瑞滨联合顺铂)治疗晚期非小细胞肺癌的近期临床疗效、短期生存率与输注化疗后的急性毒副反应。方法计算机检索PubMed、CENTRAL、EMbase、TheISIWebofKnowledgedatabases、VIP、CNKI、CBM和万方数据库,查找所有比较GP方案与NP方案化疗治疗晚期非小细胞肺癌疗效的随机临床对照实验(RCT),检索时限为2004年1月~2011年12月。依据CochraneHandbook5.0.1的质量评价标准独立进行RCT筛选、资料提取和质量评价后,按Cochrane协作网推荐的方法使用RevMan5.0软件对相关病例对照研究进行Meta分析研究。结果共纳入合格文献7项研究,共517例晚期非小细胞肺癌患者。Meta分析结果显示:GP方案相比于NP方案在治疗有效率、1年生存率、恶心呕吐反应发生率等方面差异无统计学意义(P〉0.05),初次选择GP方案的患者在发生Ⅲ度以上骨髓抑制的发生率方面明显高于NP组,一般进行预防性处理以后,患者大都可以耐受。结论GP方案与NP方案治疗晚期非小细胞肺癌疗效确切一致,且不良反应均可耐受,临床治疗时可根据患者的具体情况选择治疗方案。 Objective To systematically evaluate the curative effect of gemcitabine plus cisplatin and vinorelbine plus cisplatin for the the threatment of advanced NSCLC. Methods The databases such as PubMed, CENTRAL, EMbase, VIP, CNKI, CBM and Wanfang Data were searched to collect all randomized control trials (RCTs) about the the cura- tive effect of gemcitabine plus cisplatin and vinorelbine plus cisplatin for the treatment of advanced NSCLC. The time limit was from January 2004 to December 2011. Literatures were screened according to the inclusive and exclusive criteria by two people independently, the data were extracted, the methodological quality of the included studies was assessed in line with Cochrane Handbook 5.0.1. Meta-analysis was conducted with RevMan 5 software using the meth- ods recommended by the Cochrane Collaboration. Results Seven RCTs involving 517 advanced NSCLC patients were included. Meta analysis results show that: NACT compared to ACT in the response rate, 1 year survival rate, nausea and vomiting frequency, having no statistically significant differences, grade Ⅲ-ⅣV thrombocytopenia rate in GP group was significantly higher than the NP group. Conclusion Both GP and NP regimens are effective for NSCLC and have no significant difference, the side effects of the two regimens are different but all adverse reaction are tolerable. We can chose different treatment methods according to the specific conditions of patients.
出处 《中国医药导报》 CAS 2013年第5期58-61,共4页 China Medical Herald
关键词 GP NP 晚期非小细胞肺癌 临床疗效 系统评价 毒副作用 Gemcitabine plus Cisplatin Vinorelbine plus Cisplatin Advanced NSCLC Curative effect Systematicreview Side effects
  • 相关文献

参考文献10

二级参考文献46

  • 1谢启超,胡义德,陈正堂.GP和NP方案治疗晚期非小细胞肺癌的疗效比较研究[J].重庆医学,2004,33(7):991-993. 被引量:3
  • 2宋扬,冯英明,张贺龙,姬统理,闵婕,王宏.顺铂分别联合诺维本、健择、泰索帝治疗晚期非小细胞肺癌的临床研究[J].现代肿瘤医学,2005,13(4):494-496. 被引量:20
  • 3潘启超.长春碱类的新进展──失碳长春碱[J].癌症,1996,15(3):228-231. 被引量:276
  • 4赵霞.GP与NP方案治疗晚期NSCLC的临床对比观察[J].临床肺科杂志,2007,12(6):643-644. 被引量:2
  • 5Raez LE,Lilenbaum R. New development in chemotherapy for advanced non small cell lung eancer[J]. Curr Opin Oncol, 2006,28(2) :256-262.
  • 6Lopez Vivanco G, Viteri A, Barcclo R, et al. Biweekly administration of cisplatin /gemcitabine in advanced non-small cell lung cancer[J].Am J Clin Oncol,2005,28(5) :501-507.
  • 7Gebbia V, Galetta D, Riccardi F, et al. Vinorelbine plus cisplatin versus cisplatin plus vinclesine and mitomycin C in stage ⅢB-Ⅳ non - small cell lung carcinoma: a prospective randomized study[J]. Lung Cancer,2002,37(2) : 179-187.
  • 8Spigel DR,Greco FA.Chemotherapy in metastatic and locally advanced non-small cell lung cencer[J].Semin Surg Oncol,2003,21(2):98-110.
  • 9Sandler A.B,Nemunaitis J,Denham C,et al.PhaseⅢtrial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer[J].J Clin Oncol,2000,18(1):122-130.
  • 10Chevalier TL,Brisqand D,Douillard JY,et al.Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer:Results of a European Multicenter Trial including 612 patients[J].Clin Oncol,1994,12(2):360-367.

共引文献293

同被引文献69

  • 1刘志东,许绍发,韩毅,秦明,李福根,段勇,粱子昆.70岁以上老年人肺癌273例的外科治疗[J].中华老年医学杂志,2005,24(2):103-105. 被引量:33
  • 2韦尉东,温浙盛,苏晓东,林鹏,戎铁华,陈丽昆.899例非小细胞肺癌完全切除术后的多因素生存分析[J].癌症,2007,26(11):1231-1236. 被引量:13
  • 3Yu Y, Xu X, Du Z, et al. Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treat- ment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials [J].Caneer Chemother Pharmacol, 2012, 69(5):1265-1275.doi: 10.1007/s00280-012-1833-y.
  • 4Gao Q,Yang S,Kang MQ. Influence of survivin and Bcl-2 expres- sion on the biological behavior of non-small cell lung cancer [J].Mo- lecular Medicine Reports,2012,5(6):1409-1414.doi:10.3892/mmr. 2012.840.
  • 5Uramoto H, Sugio K, Oyama T, et al. Expression of the p53 family in lung cancer[J]. Anticancer Res,2006,26(3A):1785-1790.
  • 6Huang C, Kohno N, Inufusa H, et al. Immunohistochemical Analy- sis of Non-Small Cell Lung Cancer: Correlation with Clinical Pa- rameters and Prognosis [J]. J Korean Med Sci,2007,22:318-325.
  • 7Qin G, Sheng Y, Ming QK. Influence of survivin and Bcl-2 expres- sion on the biological behavior of non-small cell lung cancer[J]. Mol Med Rep,2012,5(6):1409-1414.doi: 10.3982/mmr.2012.840.
  • 8Yoo JY, Jung JH, Lee M, et al. Immunohistochemical analysis of non-small cell lung cancer: correlation with clinical parameters and prognosis[J]. J Korean Med Sci,2007,22(02):318-325.doi: 10.3346/ jkms.2007.22.2.318.
  • 9高禹舜,邢学忠,邵康,冯晓莉,赫捷.1826例非小细胞肺癌的预后因素分析[J].中华肿瘤杂志,2008,30(2):134-137. 被引量:16
  • 10魏巍,华东.非小细胞肺癌预后影响因素分析[J].现代肿瘤医学,2008,16(9):1549-1551. 被引量:5

引证文献7

二级引证文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部